DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: DDAVP

Summary for Tradename: DDAVP

Patents:2
Applicants:1
NDAs:3
Suppliers: see list2
drug
patent expirations by year for
 DDAVP

Clinical Trials for: DDAVP

Efficacy and Safety of IL-11 in DDAVP Unresponsive
Status: Completed Condition: Hemophilia A; Von Willebrand Disease

The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion
Status: Recruiting Condition: Gender Difference in V2 Receptor Function in Response to dDAVP Infusion; Nocturia; Nocturnal Enuresis

DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty
Status: Not yet recruiting Condition: Postoperative Ecchymosis

Desmopressin Response in the Young
Status: Completed Condition: Primary Nocturnal Enuresis

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
Status: Completed Condition: Nocturia

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
Status: Completed Condition: Nocturia

Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction
Status: Completed Condition: Platelet Dysfunction; Hemodilution; Mild Hypothermia; NSAID; Desmopressin

Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo
Status: Completed Condition: Nocturia

A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).
Status: Completed Condition: Central Diabetes Insipidus

Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic
Status: Recruiting Condition: Renal Colic; Pain

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
DDAVP
desmopressin acetate
INJECTABLE;INJECTION018938Apr 25, 1995DISCNNo<disabled><disabled>
Sanofi Aventis Us
DDAVP
desmopressin acetate
INJECTABLE;INJECTION018938Mar 30, 1984RXYes<disabled><disabled>
Sanofi Aventis Us
DDAVP
desmopressin acetate
SOLUTION;NASAL017922Approved Prior to Jan 1, 1982RXYes5,674,850<disabled><disabled>
Sanofi Aventis Us
DDAVP
desmopressin acetate
SPRAY, METERED;NASAL017922Feb 6, 1989DISCNNo5,674,850<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc